1. Home
  2. DXC vs SUPN Comparison

DXC vs SUPN Comparison

Compare DXC & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo DXC Technology Company

DXC

DXC Technology Company

HOLD

Current Price

$14.16

Market Cap

2.3B

Sector

Technology

ML Signal

HOLD

Logo Supernus Pharmaceuticals Inc.

SUPN

Supernus Pharmaceuticals Inc.

HOLD

Current Price

$45.79

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DXC
SUPN
Founded
1959
2005
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
2.6B
IPO Year
N/A
2012

Fundamental Metrics

Financial Performance
Metric
DXC
SUPN
Price
$14.16
$45.79
Analyst Decision
Hold
Strong Buy
Analyst Count
7
4
Target Price
$15.33
$63.25
AVG Volume (30 Days)
2.0M
782.6K
Earning Date
10-30-2025
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
1492.90
N/A
EPS
2.03
N/A
Revenue
$12,714,000,000.00
$681,539,000.00
Revenue This Year
N/A
$8.32
Revenue Next Year
N/A
$23.36
P/E Ratio
$6.96
N/A
Revenue Growth
N/A
4.54
52 Week Low
$11.82
$29.16
52 Week High
$23.75
$57.65

Technical Indicators

Market Signals
Indicator
DXC
SUPN
Relative Strength Index (RSI) 63.44 46.31
Support Level $11.82 $44.09
Resistance Level $12.87 $47.00
Average True Range (ATR) 0.38 1.25
MACD 0.17 0.10
Stochastic Oscillator 95.33 57.97

Price Performance

Historical Comparison
DXC
SUPN

About DXC DXC Technology Company

DXC Technology Co is a vendor-independent IT services provider. The company's operating segment includes Global Business Services (GBS) and Global Infrastructure Services (GIS). It generates maximum revenue from the GIS segment. GIS offerings include Cloud and Security; IT Outsourcing and Modern Workplace. Geographically, it derives a majority of revenue from the Other Europe region.

About SUPN Supernus Pharmaceuticals Inc.

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

Share on Social Networks: